Clinical trials: Immunoglobulin
Psoriasis
A Study for Adults With Plaque Psoriasis
In this study, we will evaluate clinical activity, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of 5 LY2525623 dosing groups compared to placebo in adults with plaque psoriasis.
- Trial name
- NCT01018810
- Testing
- LY2525623 Intravenous, LY2525623 Subcutaneous
- Where
- 28 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis
Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system, usually presenting as clinically isolated syndrome (CIS).
- Trial name
- NCT05072691
- Testing
- CSF immunoglobulin (Ig) free light chains (FLC) dosage
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Francis Corazza
Lymphoma
Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can locate cancer cells and deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00073931
- Testing
- filgrastim, sargramostim, autologous bone marrow transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Fred Hutchinson Cancer Center
Advanced / Metastatic Solid Tumors
A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors
This include two parts, Stage 1 is a dose climbing study and Stage 2 is a dose extending study.
- Trial name
- NCT05425602
- Testing
- MAX-40279-01: 50mg/70mg
- Volunteers
- 108 people
- Sponsor
- Maxinovel Pty., Ltd.
Primary Immunodeficiency Diseases
Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency
This study aims to systematically evaluate the dynamic alterations in peripheral immune subsets among patients with antibody Immunodeficiency undergoing Immunoglobulin therapy
- Trial name
- IEIPAI (NCT07516002)
- Volunteers
- 15 people
- Sponsor
- Peking University People's Hospital
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma…
- Trial name
- NCT06943872
- Testing
- Sonrotoclax, Obinutuzumab, Rituximab
- Where
- 195 sites in United States, Argentina and 19 more
- Volunteers
- 630 people
- Sponsor
- BeOne Medicines
Classical Hodgkin Lymphoma
Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma
By the implementation of the anti-PD-1 antibody pembrolizumab and given its possible synergy with RT, the aim of the present trial is to develop a chemotherapy-free first-line treatment for patients with newly diagnosed…
- Trial name
- PREFer (NCT06916416)
- Testing
- Pembrolizumab
- Volunteers
- 50 people
- Sponsor
- University of Cologne
P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer
A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
This study is a Phase 1b/2 multi-center study to assess the safety, tolerability, pharmacokinetics of CTX-009 (ABL001) in combination with Irinotecan or Paclitaxel in patients with advanced or metastatic solid tumors.
- Trial name
- NCT04492033
- Testing
- CTX-009 (ABL001), Paclitaxel, Irinotecan
- Where
- 4 sites in South Korea
- Volunteers
- 41 people
- Sponsor
- Handok Inc.
Relapsing-Remitting Multiple Sclerosis
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
To look at the ability of LY2127399 to reduce magnetic resonance imaging (MRI) lesions at 12, 16, 20, and 24 weeks compared to placebo.
- Trial name
- NCT00882999
- Testing
- LY2127399
- Where
- 63 sites in United States, Bulgaria and 11 more
- Volunteers
- 245 people
- Sponsor
- Eli Lilly and Company
SARS-CoV-2 Infection
A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults
The primary objectives of this open-label trial were to evaluate the safety and pharmacokinetics (PK) of Anti-SARS-CoV-2 Immunoglobulin (Human) Investigational Product (COVID-HIG) administered intramuscularly (IM), subcutaneously…
- Trial name
- NCT05142306
- Testing
- COVID-HIG
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Crohns Disease, Crohn's Disease
Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease
The study will include participants with moderate to severe Crohn's disease. The aim is to evaluate the safety, tolerability, and efficacy of anti-oncostatin M monoclonal antibody (mAb) GSK2330811.
- Trial name
- COSMIS (NCT04151225)
- Testing
- GSK2330811
- Sponsor
- GlaxoSmithKline
Amyloid Light-chain Amyloidosis
Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
This research study is for people who have newly diagnosed with AL (light chain) amyloidosis and have not yet received any treatment for this condition.
- Trial name
- NCT07524634
- Testing
- BCMA bispecific
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Case Comprehensive Cancer Center
SARS Virus
Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia
Early inhibition of entry and replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a very promising therapeutic approach.
- Trial name
- POLYCOR (NCT04453384)
- Testing
- XAV-19
- Where
- 34 sites in France, Martinique and 1 more
- Volunteers
- 416 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be…
- Trial name
- DREAMM 14 (NCT05064358)
- Testing
- Belantamab mafodotin
- Where
- 77 sites in United States, Argentina and 16 more
- Volunteers
- 177 people
- Sponsor
- GlaxoSmithKline
Cytomegalovirus (CMV) Infection
CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients
Cytomegalovirus (CMV) is a significant opportunistic pathogen and a major cause of morbidity and mortality in solid organ transplant recipients.
- Trial name
- NCT07009548
- Testing
- Cytogam
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Fernanda P Silveira, MD, MS
Graves Ophthalmopathy
Tocilizumab in Active Moderate-severe Graves' Orbitopathy
To treat patientis with active moderate-severe GO with the anti-IL6 receptor monoclonal antibody tocilizubam with the purpose of assesing the efficacy of therapy on active GO and on the proportion of patiens with inactivation and…
- Trial name
- TOGO (NCT04876534)
- Testing
- Tocilizumab 20 Mg/mL Intravenous Solution, MethylPREDNISolone Injectable Solution
- Where
- 4 sites in Italy
- Volunteers
- 56 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Resectable Pancreatic Adenocarcinoma
Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer
This study intends to design the prospective, exploratory, single center clinical study, using targeted EGFR fluorescence imaging agent (anti-EGFR-IR800CW) and fluorescent navigation technology, in its lymph node tracing…
- Trial name
- CISPD-6 (NCT06168552)
- Testing
- Injection of fluorescent developer (anti-EGFR-IR800CW)
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
Multiple Myeloma
Selinexor Treatment of Refractory Myeloma
This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with penta-refractory MM (Parts 1 and 2) or quad refractory MM…
- Trial name
- STORM (NCT02336815)
- Testing
- Selinexor, Dexamethasone
- Where
- 61 sites in United States, Austria and 4 more
- Volunteers
- 202 people
- Sponsor
- Karyopharm Therapeutics Inc
Systemic Lupus Erythematosus
The Anifrolumab PRIM Program
Pregnancy and infant outcomes in anifrolumab exposed pregnancies using PRegnancy outcomes Intensive Monitoring (PRIM) data: The anifrolumab PRIM program
- Trial name
- PRIM (NCT06795893)
- Testing
- Anifrolumab
- Where
- Sweden
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Gastrointestinal Cancer, Cholangiocarcinoma
Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
This study aims to find out: 1. The tolerability of Cabotamig (ARB202) in adults with advanced solid gastrointestinal tumors who failed the standard treatment. People can participate if their tumor has the CDH17 marker. 2.
- Conditions
- Gastrointestinal Cancer, Cholangiocarcinoma, Liver Cancer, Colorectal Adenocarcinoma
- Trial name
- NCT05411133
- Testing
- Cabotamig (ARB202)
- Where
- 3 sites in Australia, Hong Kong
- Volunteers
- 33 people
- Sponsor
- Arbele Pty Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.